Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Fondazione Italiana Linfomi - ETS
The study aim is to evaluate the toxicity and activity of a therapeutic approach to high doses with support of peripheral blood stem cells (PBSC) in patients aged ≥ 65 and ≤75 years, chemosensitive relapsed or refractory to therapy first line in terms of event free survival (EFS) and treatment related mortality (TRM)
Age
65–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Diagnosis of NHL
relapse and refractory pts
age ≥ 65 and ≤75
ECOG performance status \<2
FIT patients (Instrumental Activity of Daily Living (IADL)=8, Activity of Daily Living (ADL)=6, Cumulative Illness Rating Scale (CIRS) =0 SCORE=3-4, \<5 SCORE=2 )
evaluable disease
no RT since 3 week
absolute neutrophil count \>= 1500/mm3 and platelets \>= 100.000/106L
Creatinin \<= 1.5 mg/dL and clearance \>40 ml/min/24 h
